AUDACAS# 479413-70-2 |
- Pioglitazone
Catalog No.:BCC4927
CAS No.:111025-46-8
- GW501516
Catalog No.:BCC2268
CAS No.:317318-70-0
- WY-14643 (Pirinixic Acid)
Catalog No.:BCC2265
CAS No.:50892-23-4
- L-165041
Catalog No.:BCC1687
CAS No.:79558-09-1
- Sodium 4-amiropparaty Hyalrate
Catalog No.:BCC3855
CAS No.:94-16-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 479413-70-2 | SDF | Download SDF |
PubChem ID | 10069117 | Appearance | Powder |
Formula | C23H40N2O3 | M.Wt | 392.58 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 62.5 mg/mL (159.20 mM; Need ultrasonic) | ||
Chemical Name | 12-(1-adamantylcarbamoylamino)dodecanoic acid | ||
SMILES | C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCCCCCCCC(=O)O | ||
Standard InChIKey | XLGSEOAVLVTJDH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H40N2O3/c26-21(27)10-8-6-4-2-1-3-5-7-9-11-24-22(28)25-23-15-18-12-19(16-23)14-20(13-18)17-23/h18-20H,1-17H2,(H,26,27)(H2,24,25,28) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
AUDA Dilution Calculator
AUDA Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5473 mL | 12.7363 mL | 25.4725 mL | 50.945 mL | 63.6813 mL |
5 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL | 10.189 mL | 12.7363 mL |
10 mM | 0.2547 mL | 1.2736 mL | 2.5473 mL | 5.0945 mL | 6.3681 mL |
50 mM | 0.0509 mL | 0.2547 mL | 0.5095 mL | 1.0189 mL | 1.2736 mL |
100 mM | 0.0255 mL | 0.1274 mL | 0.2547 mL | 0.5095 mL | 0.6368 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AUDA
- NBQX disodium salt
Catalog No.:BCC6907
CAS No.:479347-86-9
- CNQX disodium salt
Catalog No.:BCC6908
CAS No.:479347-85-8
- TC OT 39
Catalog No.:BCC7958
CAS No.:479232-57-0
- MMPIP hydrochloride
Catalog No.:BCC7528
CAS No.:479077-02-6
- [Orn8]-Urotensin II
Catalog No.:BCC5793
CAS No.:479065-85-5
- Aucubin
Catalog No.:BCN5355
CAS No.:479-98-1
- Vitexicarpin
Catalog No.:BCN5020
CAS No.:479-91-4
- Artemetin
Catalog No.:BCN5547
CAS No.:479-90-3
- Canthin-6-one
Catalog No.:BCN5546
CAS No.:479-43-6
- Indirubin
Catalog No.:BCN2385
CAS No.:479-41-4
- Cotoin
Catalog No.:BCN5545
CAS No.:479-21-0
- Atranorin
Catalog No.:BCN5544
CAS No.:479-20-9
- 1-O-galloyl-2-O-cinnamoyl-beta-d-glucose
Catalog No.:BCC3967
CAS No.:
- CP-809101
Catalog No.:BCC1498
CAS No.:479683-64-2
- Eleutherol
Catalog No.:BCN8480
CAS No.:480-00-2
- Astragalin
Catalog No.:BCN5549
CAS No.:480-10-4
- Oroxylin A
Catalog No.:BCN5363
CAS No.:480-11-5
- Izalpinine
Catalog No.:BCN3682
CAS No.:480-14-8
- Morin
Catalog No.:BCN1028
CAS No.:480-16-0
- Taxifolin
Catalog No.:BCN5550
CAS No.:480-18-2
- Isorhamnetin
Catalog No.:BCN5551
CAS No.:480-19-3
- Aromadendrin
Catalog No.:BCN5552
CAS No.:480-20-6
- Orobol
Catalog No.:BCN5553
CAS No.:480-23-9
- Mellein
Catalog No.:BCN4785
CAS No.:480-33-1
Ingestion of the epoxide hydrolase inhibitor AUDA modulates immune responses of the mosquito, Culex quinquefasciatus during blood feeding.[Pubmed:27369469]
Insect Biochem Mol Biol. 2016 Sep;76:62-69.
Epoxide hydrolases (EHs) are enzymes that play roles in metabolizing xenobiotic epoxides from the environment, and in regulating lipid signaling molecules, such as juvenile hormones in insects and epoxy fatty acids in mammals. In this study we fed mosquitoes with an epoxide hydrolase inhibitor AUDA during artificial blood feeding, and we found the inhibitor increased the concentration of epoxy fatty acids in the midgut of female mosquitoes. We also observed ingestion of AUDA triggered early expression of defensin A, cecropin A and cecropin B2 at 6 h after blood feeding. The expression of cecropin B1 and gambicin were not changed more than two fold compared to controls. The changes in gene expression were transient possibly because more than 99% of the inhibitor was metabolized or excreted at 42 h after being ingested. The ingestion of AUDA also affected the growth of bacteria colonizing in the midgut, but did not affect mosquito longevity, fecundity and fertility in our laboratory conditions. When spiked into the blood, EpOMEs and DiHOMEs were as effective as the inhibitor AUDA in reducing the bacterial load in the midgut, while EETs rescued the effects of AUDA. Our data suggest that epoxy fatty acids from host blood are immune response regulators metabolized by epoxide hydrolases in the midgut of female mosquitoes, inhibition of which causes transient changes in immune responses, and affects growth of microbes in the midgut.
Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.[Pubmed:24311719]
Drug Metab Dispos. 2014 Feb;42(2):294-300.
The environmental toxin and carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) binds and activates the transcription factor aryl hydrocarbon receptor (AHR), inducing CYP1 family cytochrome P450 enzymes. CYP1A2 and its avian ortholog CYP1A5 are highly active arachidonic acid epoxygenases. Epoxygenases metabolize arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) and selected monohydroxyeicosatetraenoic acids (HETEs). EETs can be further metabolized by epoxide hydrolases to dihydroxyeicosatrienoic acids (DHETs). As P450-arachidonic acid metabolites affect vasoregulation, responses to ischemia, inflammation, and metabolic disorders, identification of their production in vivo is needed to understand their contribution to biologic effects of TCDD and other AHR activators. Here we report use of an acetonitrile-based extraction procedure that markedly increased the yield of arachidonic acid products by lipidomic analysis over a standard solid-phase extraction protocol. We show that TCDD increased all four EETs (5,6-, 8,9-, 11,12-, and 14,15-), their corresponding DHETs, and 18- and 20-HETE in liver in vivo and increased 5,6-EET, the four DHETs, and 18-HETE in heart, in a chick embryo model. As the chick embryo heart lacks arachidonic acid-metabolizing activity, the latter findings suggest that arachidonic acid metabolites may travel from their site of production to a distal organ, i.e., heart. To determine if the TCDD-arachidonic acid-metabolite profile could be altered pharmacologically, chick embryos were treated with TCDD and the soluble epoxide hydrolase inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA). Cotreatment with AUDA increased hepatic EET-to-DHET ratios, indicating that the in vivo profile of P450-arachidonic acid metabolites can be modified for potential therapeutic intervention.
Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases.[Pubmed:25975094]
Pharmazie. 2015 Jan;70(1):24-8.
In this study, we aimed to detect the effects of the soluble epoxide hydrolase (sEH) inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) on atherosclerotic diseases and to explore its mechanism. The atherosclerosis animal model was constructed by ApoE-/- mice. To determine the optimal therapeutic concentration of AUDA, different concentrations of AUDA were infused into ApoE-/- mice, with controls receiving infusions of normal saline alone. Mouse body weight and serum total cholesterol, triglyceride, LDL and HDL levels were measured. The western blotting (WB) method was used to detect the expression of TLR4 and NFKB in the aortic wall of the AUDA-treated and control mice. After the animals were sacrificed, we performed Oil Red O staining of the aortic sinus atherosclerotic plaque area followed by quantitative analysis of the aortic atherosclerotic plaque size and the percentage of lumen area in the two groups of mice. The expression levels of inflammatory cytokines, adhesion molecules and chemokines in the AUDA group were significantly decreased compared to the saline-treatment group (P < 0.05). The optimal AUDA concentration was found to be 0.35 ml/mg. AUDA significantly inhibited the expression of TLR4 and NFkappaB in ApoE-/- mouse aortas and reduced the aortic sinus plaque area of the ApoE-/- mouse group (P < 0.05). In conclusion, AUDA can regulate blood lipid balance, which may be one of the mechanisms for its protective effects on the cardiovascular system.
Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.[Pubmed:18508449]
Front Biosci. 2008 May 1;13:3480-7.
In stroke-prone spontaneously hypertensive rats (SHRSP) end-organ damage is markedly accelerated by high-salt (HS) intake. Since epoxyeicosatrienoic acids (EETs) possess vasodepressor and natriuretic activities, we examined whether a soluble epoxide hydrolase (sEH) inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), to inhibit the metabolism of EETs, would protect against pathologic changes in SHRSP. Seven-week-old male SHRSP were treated as follows: normal salt (NS), NS + AUDA, HS and HS + AUDA. Systolic blood pressure (SBP) (205 +/- 4 v 187 +/- 7 mmHg) and proteinuria (3.7 +/- 0.2 v 2.6 +/- 0.2 mg/6 h), but not plasma EETs (11.0 +/- 0.9 v 9.7 +/- 1.1 ng/ml), were significantly increased at 9 weeks of age in HS v NS SHRSP. HS was associated with fibrinoid degeneration and hypertrophy of arterioles in the kidney and perivascular fibrosis and contraction band necrosis in the heart. AUDA ameliorated these early salt-dependent changes in saline-drinking SHRSP and increased plasma levels of EETs but did not affect water and electrolyte excretion. sEH inhibition may provide a therapeutic strategy for treating salt-sensitive hypertension and its sequelae.